EPISODE · Mar 9, 2022 · 33 MIN
Targeting the pathobiology of ESCC: Potential impact of immunotherapy on clinical practice
from touchPODCAST · host touchpodcast
touchEXPERT OPINIONS for touchONCOLOGY Listen to leading experts provide an update on the underlying pathobiology of esophageal squamous cell carcinoma, and review current and emerging therapies. The experts Prof. Ken Kato, National Cancer Center Hospital, Tokyo, Japan Dr Jean-Phillippe Metges, Brest University Hospital, Brest, France Dr Radka Obermannova, Masaryk Memorial Cancer Institute Brno, Czech Republic This touchPODCAST is for HCPs only. This activity is funded by an unrestricted independent medical education grant from from Novartis. This activity is provided by touchIME. For further information visit our website: https://touchoncologyime.org/targeting-pathobio-of-ESCC-and-emerging-impact-of-IO
Embed this episode
Ready to play
Targeting the pathobiology of ESCC: Potential impact of immunotherapy on clinical practice
No transcript for this episode yet
Similar Episodes
No similar episodes found.
Similar Podcasts
No similar podcasts found.